 Biomarkers, Tumor
"Biomarkers, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS.
| Descriptor ID |
D014408
|
| MeSH Number(s) |
D23.101.140
|
| Concept/Terms |
Biomarkers, Tumor- Biomarkers, Tumor
- Tumor Biomarkers
- Markers, Biological Tumor
- Tumor Markers, Biological
- Markers, Tumor Metabolite
- Tumor Metabolite Markers
- Metabolite Markers, Tumor
- Marker, Tumor Metabolite
- Metabolite Marker, Tumor
- Tumor Metabolite Marker
- Tumor Markers, Biologic
- Biologic Tumor Markers
- Markers, Biologic Tumor
- Marker, Biologic Tumor
- Biologic Tumor Marker
- Tumor Marker, Biologic
- Biochemical Tumor Markers
- Markers, Biochemical Tumor
- Marker, Biochemical Tumor
- Biochemical Tumor Marker
- Tumor Marker, Biochemical
- Tumor Markers, Biochemical
- Carcinogen Markers
- Markers, Carcinogen
- Markers, Neoplasm Metabolite
- Neoplasm Metabolite Markers
- Marker, Neoplasm Metabolite
- Metabolite Marker, Neoplasm
- Neoplasm Metabolite Marker
- Metabolite Markers, Neoplasm
- Biological Tumor Markers
- Biological Tumor Marker
- Tumor Marker, Biological
- Marker, Biological Tumor
Markers, Tumor- Markers, Tumor
- Tumor Markers
- Biomarkers, Cancer
- Cancer Biomarkers
|
Below are MeSH descriptors whose meaning is more general than "Biomarkers, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Tumor".
This graph shows the total number of publications written about "Biomarkers, Tumor" by people in this website by year, and whether "Biomarkers, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 3 | 5 | 8 | | 1990 | 13 | 5 | 18 | | 1991 | 11 | 5 | 16 | | 1992 | 15 | 10 | 25 | | 1993 | 14 | 10 | 24 | | 1994 | 21 | 13 | 34 | | 1995 | 15 | 10 | 25 | | 1996 | 14 | 17 | 31 | | 1997 | 16 | 15 | 31 | | 1998 | 22 | 26 | 48 | | 1999 | 20 | 26 | 46 | | 2000 | 23 | 34 | 57 | | 2001 | 39 | 31 | 70 | | 2002 | 37 | 46 | 83 | | 2003 | 56 | 60 | 116 | | 2004 | 75 | 57 | 132 | | 2005 | 69 | 84 | 153 | | 2006 | 86 | 77 | 163 | | 2007 | 88 | 64 | 152 | | 2008 | 100 | 67 | 167 | | 2009 | 100 | 86 | 186 | | 2010 | 83 | 118 | 201 | | 2011 | 119 | 121 | 240 | | 2012 | 121 | 115 | 236 | | 2013 | 141 | 99 | 240 | | 2014 | 154 | 97 | 251 | | 2015 | 147 | 104 | 251 | | 2016 | 145 | 142 | 287 | | 2017 | 136 | 131 | 267 | | 2018 | 87 | 100 | 187 | | 2019 | 16 | 17 | 33 |
To return to the timeline, click here.
Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.
-
Liang DH, Hall C, Lucci A. Circulating Tumor Cells in Breast Cancer. Recent Results Cancer Res. 2020; 215:127-145.
-
Fu C, Xu X, Lu W, Nie L, Yin T, Wu D. Increased expression of long non-coding RNA CCAT2 predicts poorer prognosis in patients with hepatocellular carcinoma. Medicine (Baltimore). 2019 Oct; 98(42):e17412.
-
Hinchcliff E, Paquette C, Roszik J, Kelting S, Stoler MH, Mok SC, Yeung TL, Zhang Q, Yates M, Peng W, Hwu P, Jazaeri A. Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature. Cancer Immunol Immunother. 2019 Sep; 68(9):1515-1526.
-
Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. N Engl J Med. 2019 08 22; 381(8):727-738.
-
Wu TH, Hsiue EH, Yang JC. Opportunities of circulating tumor DNA in lung cancer. Cancer Treat Rev. 2019 Aug; 78:31-41.
-
Corsini EM, Mitchell KG, Mehran RJ, Rice DC, Sepesi B, Walsh GL, Swisher SG, Roth JA, Hofstetter WL, Vaporciyan AA, Morris VK, Antonoff MB. Colorectal cancer mutations are associated with survival and recurrence after pulmonary metastasectomy. J Surg Oncol. 2019 Sep; 120(4):729-735.
-
Banks M, Graham D, Jansen M, Gotoda T, Coda S, di Pietro M, Uedo N, Bhandari P, Pritchard DM, Kuipers EJ, Rodriguez-Justo M, Novelli MR, Ragunath K, Shepherd N, Dinis-Ribeiro M. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 2019 09; 68(9):1545-1575.
-
Baljevic M, Orlowski RZ. Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma. Expert Opin Drug Metab Toxicol. 2019 Jun; 15(6):459-473.
-
Schefler AC, Koca E, Bernicker EH, Correa ZM. Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 2019 Jul; 257(7):1541-1545.
-
Nagarajan P, El-Hadad C, Gruschkus SK, Ning J, Hudgens CW, Sagiv O, Gross N, Tetzlaff MT, Esmaeli B. PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma. Invest Ophthalmol Vis Sci. 2019 05 01; 60(6):2388-2398.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|